glucose intolerance

Sequoyitol (5-O-Methyl-Myo-Inositol), a methyl derivative of inositol, is often used to treat diabetes.

Exicorilant is a selective and oral active glucocorticoid receptor (GR) antagonist (Ki: 7 nM) and it also has the potential to overcome adiposity, glucose intolerance, and dyslipidemia.

JTT-553 is a DGAT1 inhibitor with an IC50 of 2.38 nM. It effectively reduces plasma levels of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and liver triglycerides (TG). JTT-553 enhances insulin-dependent glucose absorption and glucose intolerance in the adipose tissue of diet-induced obese (DIO) mice. In KK-Ay mice, it lowers TNF-α mRNA levels and elevates GLUT4 mRNA levels in adipose tissue. By contributing to weight loss, JTT-553 improves insulin resistance in adipose tissue and overall glucose metabolism. This compound is useful for research on obesity and type 2 diabetes mellitus (T2DM).

BDM44768 is an insulin-degrading enzyme (IDE) inhibitor that acts by inducing glucose intolerance.

T-1095A is an active metabolite of T-1095, a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs). Chronic administration of T-1095 (0.1% w w(-1) pellet chow, for 12 weeks) decreased blood glucose and haemoglobin A(1C) levels, and improved

CPT-157633 is a difluoro-phosphonomethyl phenylalanine derivative that acts as a potent inhibitor of the enzyme PTP1B. It effectively prevents the development of glucose intolerance induced by binge drinking.

DS-1558 is a potent and orally available GPR40 agonist.DS-1558 was found to have potent glucose lowering effects during an oral glucose tolerance test in ZDF rats. DS-1558 significantly and dose-dependently improved hyperglycemia and increased insulin secretion during the oral glucose tolerance test in Zucker fatty rats, the model of insulin resistance and glucose intolerance. DS-1558 not only increased the glucose-stimulated insulin secretion by GLP-1 but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats.

ATF3 inducer 1 is an efficient ATF3 inducer with lipid-lowering and anti-hyperglycemic activities. It alleviates glucose intolerance and insulin resistance induced by high-fat diet (HFD) and ameliorates liver steatosis induced by HFD. It can be used for research on obesity.